SCHEMBL16129679

SCHEMBL16129679

CS(=O)(=O)Cc1ccc(C(=O)Nc2ccc(-c3ccccc3)cc2)cc1NC(=O)CCl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.52
NPC1 O15118 1/20 0.52
MITF O75030 1/20 0.52
ALDH1A1 P00352 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
WNT3A P56704 6/20 0.50
SETD7 Q8WTS6 1/20 0.46
PRMT1 Q99873 1/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
PSMD14 O00487 1/20 0.46
POLB P06746 1/20 0.46
RECQL P46063 1/20 0.46
CACNA1B Q00975 1/20 0.46
APBA1 Q02410 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
SAE1 Q9UBE0 1/20 0.46
UBA2 Q9UBT2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16098936 0.83 WNT3A (0.73) SMN1; SMN2WNT3AMEN1KMT2A
SCHEMBL16102995 0.82 WNT3A (0.73) NPC1RAB9AWNT3AMEN1KMT2A
SCHEMBL17539213 0.82 ALDH1A1 (0.51) HTTNPC1MITFALDH1A1RAB9A
SCHEMBL16129614 0.82 MEN1 (0.54) HTTSMN1; SMN2SETD7PRMT1MEN1
SCHEMBL16098059 0.82 WNT3A (0.73) ALDH1A1SMN1; SMN2WNT3AMEN1MAPT
SCHEMBL16129646 0.81 SMN1; SMN2 (0.49) HTTNPC1MITFALDH1A1RAB9A
SCHEMBL16104957 0.80 WNT3A (0.55) WNT3AMEN1KMT2A
SCHEMBL16105048 0.80 SMN1; SMN2 (0.59) HTTNPC1MITFALDH1A1RAB9A
SCHEMBL16129676 0.79 HDAC8 (0.64) HTTNPC1MITFALDH1A1RAB9A
SCHEMBL16098779 0.79 SMN1; SMN2 (0.47) HTTNPC1MITFALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160052898-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
WO-2014147182-A2 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052898-A1 NOVEL COMPOUNDS AADAC, NAT1, CCNA1 HTT 1838/4885NPC1 933/4885MITF 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.